Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Alligator Bioscience AB ( (SE:ATORX) ) is now available.
Alligator Bioscience AB has increased its total number of shares and votes during March 2026 following the exercise of warrants in series TO 14 that were issued as part of a rights issue of units carried out in late 2025. As of 31 March 2026, the company has 628,106,848 outstanding ordinary shares, each carrying one vote, slightly diluting existing shareholders but strengthening its capital base and aligning with its regulated market obligations for transparency.
The change in share capital reflects ongoing investor participation in earlier financing measures, indicating continued access to equity funding for the biotech group. The updated share count clarifies the ownership and voting structure for stakeholders and supports compliance with the Financial Instruments Trading Act, which governs how Swedish listed companies report changes in shares and votes.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Swedish biotechnology company based in Lund that operates within the life sciences sector. The company focuses on developing innovative biological therapies, with its shares listed and traded on a regulated market, making it subject to Swedish financial disclosure requirements.
YTD Price Performance: -50.89%
Average Trading Volume: 5,268,936
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK88.41M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.